JP2000507939A5 - - Google Patents

Download PDF

Info

Publication number
JP2000507939A5
JP2000507939A5 JP1997533791A JP53379197A JP2000507939A5 JP 2000507939 A5 JP2000507939 A5 JP 2000507939A5 JP 1997533791 A JP1997533791 A JP 1997533791A JP 53379197 A JP53379197 A JP 53379197A JP 2000507939 A5 JP2000507939 A5 JP 2000507939A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1997533791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000507939A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/005071 external-priority patent/WO1997034618A1/en
Publication of JP2000507939A publication Critical patent/JP2000507939A/ja
Publication of JP2000507939A5 publication Critical patent/JP2000507939A5/ja
Withdrawn legal-status Critical Current

Links

JP9533791A 1996-03-22 1997-03-21 中枢神経系の虚血または外傷後のポリペプチド成長因子の投与 Withdrawn JP2000507939A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62044496A 1996-03-22 1996-03-22
US08/620,444 1996-03-22
PCT/US1997/005071 WO1997034618A1 (en) 1996-03-22 1997-03-21 Administration of polypeptide growth factors following central nervous system ischemia or trauma

Publications (2)

Publication Number Publication Date
JP2000507939A JP2000507939A (ja) 2000-06-27
JP2000507939A5 true JP2000507939A5 (cg-RX-API-DMAC10.html) 2004-12-02

Family

ID=24485972

Family Applications (2)

Application Number Title Priority Date Filing Date
JP9533791A Withdrawn JP2000507939A (ja) 1996-03-22 1997-03-21 中枢神経系の虚血または外傷後のポリペプチド成長因子の投与
JP53358397A Expired - Fee Related JP4847634B2 (ja) 1996-03-22 1997-03-21 中枢神経系の虚血または外傷の機能的回復を増大させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP53358397A Expired - Fee Related JP4847634B2 (ja) 1996-03-22 1997-03-21 中枢神経系の虚血または外傷の機能的回復を増大させる方法

Country Status (11)

Country Link
US (4) US6407060B1 (cg-RX-API-DMAC10.html)
EP (3) EP0904093A4 (cg-RX-API-DMAC10.html)
JP (2) JP2000507939A (cg-RX-API-DMAC10.html)
KR (1) KR20000064752A (cg-RX-API-DMAC10.html)
CN (1) CN1181885C (cg-RX-API-DMAC10.html)
AT (2) ATE244574T1 (cg-RX-API-DMAC10.html)
AU (2) AU734312B2 (cg-RX-API-DMAC10.html)
CA (2) CA2249368A1 (cg-RX-API-DMAC10.html)
DE (2) DE69723429T3 (cg-RX-API-DMAC10.html)
ES (1) ES2201287T5 (cg-RX-API-DMAC10.html)
WO (2) WO1997034618A1 (cg-RX-API-DMAC10.html)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
ATE343635T1 (de) 1993-05-12 2006-11-15 Genetics Inst Llc Bmp-11 zusammenstellungen
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
CA2176942C (en) 1993-12-07 2011-11-01 Anthony J. Celeste Bmp-12, bmp-13 and tendon-inducing compositions thereof
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues
ES2226125T3 (es) 1997-05-05 2005-03-16 Curis, Inc. Terapias para insuficiencia renal aguda.
EP0985149A1 (en) * 1997-05-30 2000-03-15 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
AU1706499A (en) * 1997-12-04 1999-06-16 Curis, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
DE19837230A1 (de) * 1998-08-17 2000-03-09 Jean Krutmann Neurotrophin-4 zur Behandlung von Tumoren neuroektodermalen Ursprungs
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
CN1753686A (zh) * 1999-08-18 2006-03-29 综合医院公司 用于促进从中枢神经系统损伤中恢复的方法、组合物和试剂盒
US6749850B1 (en) 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
ES2225241T3 (es) 1999-10-15 2005-03-16 Genetics Institute, Llc Formulaciones de acido hialuronico para suministrar proteinas osteogenicas.
US7060676B2 (en) 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US20020119923A1 (en) * 2000-06-01 2002-08-29 Benowitz Larry I. Methods and compositions for producing a neurosalutary effect in a subject
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
ATE393573T1 (de) 2001-06-01 2008-05-15 Wyeth Corp Zusammensetzungen für die systemische verabreichung von sequenzen, die für knochenmorphogenese-proteinen kodieren
CA2448591A1 (en) * 2001-06-01 2002-12-12 Xcyte Therapies, Inc. T cell induced tissue repair and regeneration
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US20060259014A1 (en) 2002-05-22 2006-11-16 Surgimark, Inc. Aspirator sleeve and suction handle
US20040229292A1 (en) * 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
CA2504287A1 (en) 2002-11-26 2004-06-10 Nobex Corporation Natriuretic compounds, conjugates, and uses thereof
ATE481476T1 (de) 2003-05-08 2010-10-15 Life Technologies Corp Erzeugung und isolierung antigenspezifischer t- zellen
EP2789342A1 (en) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
WO2006002262A2 (en) * 2004-06-21 2006-01-05 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
WO2006012365A2 (en) * 2004-07-20 2006-02-02 University Of Maryland Protease inhibitor
US20090082263A1 (en) * 2004-07-29 2009-03-26 Anges, Mg, Inc. Drug and method for improving brain function
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
EP2927241A1 (en) 2005-09-20 2015-10-07 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
US20090233842A1 (en) 2005-11-12 2009-09-17 Prtzker Neuropsychiatric Research Fund Llc Fgf2-related methods for diagnosing and treating depression
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
PL2121142T3 (pl) * 2007-01-25 2013-09-30 Biopharm Ges Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Zastosowanie gdf-5 do poprawy lub utrzymywania wyglądu skóry
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CN101801405A (zh) 2007-08-07 2010-08-11 先进科技及再生医学有限责任公司 包含于酸性水溶液中的gdf-5的蛋白质配方
CN102026619A (zh) * 2008-04-14 2011-04-20 先进科技及再生医学有限责任公司 液体缓冲的gdf-5制剂
CA2752160A1 (en) * 2009-02-12 2010-08-19 Stryker Corporation Compositions and methods for minimally-invasive systemic delivery of proteins including tgf-.beta. superfamily members
AU2010213575B2 (en) * 2009-02-12 2013-11-14 Stryker Corporation Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease
CN102369212B (zh) 2009-03-12 2015-12-16 哈瑟投资公司 具有降低的bmp拮抗剂敏感性的骨形成蛋白2(bmp2)变体
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
US20110224410A1 (en) 2009-09-17 2011-09-15 Hile David Buffers for Controlling the pH of Bone Morphogenetic Proteins
JP2013514811A (ja) 2009-12-22 2013-05-02 ストライカー コーポレイション 免疫原性が抑制されたｂｍｐ−７変異体
CN101822815A (zh) * 2010-04-29 2010-09-08 广东八加一医药有限公司 系列多肽小分子在制备防治缺血性脑血管疾病药物中的应用
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
AU2011292810B2 (en) 2010-08-20 2015-04-30 Wyeth Llc Designer osteogenic proteins
AU2012225784B2 (en) * 2011-03-04 2016-03-17 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
KR101274930B1 (ko) * 2011-06-03 2013-06-17 전남대학교산학협력단 골 형성 또는 혈관신생 촉진용 펩타이드 ｂｆｐ 4 및 이의 용도
RU2014105513A (ru) * 2011-07-19 2015-08-27 Трасос Инновэйшн, Инк. Противофиброзные пептиды и их применение в способах лечения заболеваний и расстройств, характеризующихся фиброзом
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
DK2981822T3 (da) 2013-05-06 2020-12-07 Scholar Rock Inc Sammensætninger og fremgangsmåder til vækstfaktormodulation
EP3007719B1 (en) * 2013-06-11 2021-03-17 President and Fellows of Harvard College Methods and compositions for increasing neurogenesis and angiogenesis
AU2016218977C1 (en) 2015-02-13 2023-03-23 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
MX2021000157A (es) * 2018-07-03 2021-12-10 Venturis Therapeutics Inc Composiciones y métodos para tratar el derrame cerebral.
CN115190886A (zh) * 2020-02-20 2022-10-14 马斯特里赫特大学 循环bmp10（骨形态发生蛋白10）的检测方法
CA3179133A1 (en) * 2020-05-19 2021-11-25 Elevian, Inc. Methods and compositions for treating stroke
WO2024259004A1 (en) * 2023-06-13 2024-12-19 Bedford Research Foundation Systems and methods of cell transport at ambient temperature

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440860A (en) 1980-01-18 1984-04-03 The Children's Medical Center Corporation Stimulating cell growth
US4296100A (en) 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
DE3110560A1 (de) 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
EP0105014B1 (en) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
US4971952A (en) 1986-03-06 1990-11-20 Collagen Corporation Method of treating inflammation with cartilage inducing factor
US4806523A (en) 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4861757A (en) 1986-11-14 1989-08-29 Institute Of Molecular Biology Wound healing and bone regeneration using PDGF and IGF-I
EP0269408A3 (en) 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
US4797277A (en) 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5108753A (en) 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
JPH0262829A (ja) 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤
US4983581A (en) 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
HU201095B (en) 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
WO1990000619A1 (en) 1988-07-08 1990-01-25 University College London Analysis of cell modifying substances
WO1990000900A1 (en) 1988-07-20 1990-02-08 Amgen Inc. Method of treating inflammatory disorders by reducing phagocyte activation
US5057494A (en) 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5106626A (en) 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US5002965A (en) 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
US5118791A (en) 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
IL97365A0 (en) * 1991-02-27 1992-05-25 Yeda Res & Dev Pharmaceutical compositions comprising a lymphokine
US5158934A (en) 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
EP0448704B1 (en) 1989-10-17 1998-06-17 Stryker Corporation Osteogenic devices
US5108989A (en) 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair
JPH06500466A (ja) 1990-06-15 1994-01-20 カーネギー インスチチューション オブ ワシントン Ｇｄｆ―１
EP0550625B1 (en) 1990-09-26 2003-11-05 Genetics Institute, LLC Bmp-5 derivatives
JPH07500487A (ja) 1990-10-18 1995-01-19 ストライカー コーポレイション 骨形成ペプチド
CA2096441A1 (en) 1990-11-16 1992-05-17 Celtrix Pharmaceuticals, Inc. Heterodimer of b-type transforming growth factors 2 and 3
DK0564502T3 (da) 1990-11-27 2002-05-13 Univ Loyola Chicago Vævsforseglingsmiddel og vækstfaktorholdige præparater, der fremmer accelereret sårheling
CA2071912C (en) 1990-11-30 2002-10-15 Hanne Bentz Use of a bone morphogenetic protein in synergistic combination with tgf-beta for bone repair
DK0575555T3 (da) * 1991-03-11 2001-11-05 Curis Inc Proteininduceret morfogenese
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
AU662155B2 (en) 1991-05-10 1995-08-24 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
JPH06500574A (ja) 1991-05-10 1994-01-20 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ アクチビン／ＴＧＦ―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生
JP3351525B2 (ja) 1991-06-21 2002-11-25 ジェネティックス・インスティテュート・インコーポレイテッド 骨形成性蛋白医薬処方物
JP3485917B2 (ja) 1991-06-25 2004-01-13 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー Ｂｍｐ−９蛋白
CA2116562C (en) 1991-08-30 1999-04-13 Thangavel Kuberasampath Morphogen-induced modulation of inflammatory response
CA2116560C (en) 1991-08-30 2002-01-08 Charles M. Cohen Morphogenic protein screening method
WO1993005751A2 (en) 1991-08-30 1993-04-01 Creative Biomolecules, Inc. Osteogenic proteins in the treatment of bone deseases
JP3504263B2 (ja) 1991-11-04 2004-03-08 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー 組み換え型骨形態形成蛋白ヘテロダイマー、組成物および使用法
AU3129793A (en) * 1991-11-08 1993-06-07 General Hospital Corporation, The Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
DE69228949T2 (de) * 1991-11-22 1999-09-16 Auckland Uniservices Ltd., Auckland Tgf-beta zur verbesserung der regeneration von neuronalem gewebe
DE19525416A1 (de) † 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
JP4344012B2 (ja) * 1992-07-31 2009-10-14 ストライカー・コーポレーション 組織形成因子誘導による神経の再生と修復
ES2061380B1 (es) * 1992-11-23 1995-07-01 Boehringer Ingelheim Espana Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
EP0716610B1 (en) 1993-08-26 2006-05-17 Genetics Institute, LLC Human bone morphogenetic proteins for use in neural regeneration
WO1995006656A1 (en) 1993-09-03 1995-03-09 The Regents Of The University Of California Neural tissue affecting factor and compositions
DE69434934D1 (de) 1993-10-14 2007-04-12 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
AU6787594A (en) 1994-03-10 1995-09-25 Human Genome Sciences, Inc. Bone morphogenic protein-10
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues

Similar Documents

Publication Publication Date Title
JP2000502280A5 (cg-RX-API-DMAC10.html)
JP2000501771A5 (cg-RX-API-DMAC10.html)
JP2000501599A5 (cg-RX-API-DMAC10.html)
JP2000501018A5 (cg-RX-API-DMAC10.html)
JP2000500076A5 (cg-RX-API-DMAC10.html)
JP2000501324A5 (cg-RX-API-DMAC10.html)
JP2000500055A5 (cg-RX-API-DMAC10.html)
JP2000502472A5 (cg-RX-API-DMAC10.html)
JP2000507939A5 (cg-RX-API-DMAC10.html)
JP2000501338A5 (cg-RX-API-DMAC10.html)
JP2000501825A5 (cg-RX-API-DMAC10.html)
JP2000500874A5 (cg-RX-API-DMAC10.html)
JP2000502425A5 (cg-RX-API-DMAC10.html)
JP2000502485A5 (cg-RX-API-DMAC10.html)
JP2000502568A5 (cg-RX-API-DMAC10.html)
JP2000501774A5 (cg-RX-API-DMAC10.html)
JP2000500912A5 (cg-RX-API-DMAC10.html)
JP2000502570A5 (cg-RX-API-DMAC10.html)
JP2000501876A5 (cg-RX-API-DMAC10.html)
JP2000501744A5 (cg-RX-API-DMAC10.html)
JP2000501229A5 (cg-RX-API-DMAC10.html)
JP2000502316A5 (cg-RX-API-DMAC10.html)
JP2000500857A5 (cg-RX-API-DMAC10.html)
JP2000502714A5 (cg-RX-API-DMAC10.html)
JP2000501569A5 (cg-RX-API-DMAC10.html)